21c056f9ffed19aa000ef1a9a77d66028e3d0daf
papers/loveGeneticLandscapeMutations2012.md
| ... | ... | @@ -8,31 +8,31 @@ bibliography: 'morinlab.bib' |
| 8 | 8 | # Summary |
| 9 | 9 | |
| 10 | 10 | The 2012 study provided foundational insights into the genetic landscape of Burkitt lymphoma (BL), |
| 11 | -identifying recurrent mutations in genes such as **MYC**, **ID3**, **ARID1A**, **SMARCA4**, and **TP53**. |
|
| 11 | +describing recurrent mutations in genes such as *MYC*, *ID3*, *ARID1A*, *SMARCA4*, and *TP53*. |
|
| 12 | 12 | Subsequent research has both validated and expanded upon these findings. Although this study identified some genes that are commonly mutated in BL. Some of its novel findings are of questionable |
| 13 | 13 | significance in BL. |
| 14 | 14 | |
| 15 | 15 | ## Reproduced Findings |
| 16 | -- **ID3 Mutations**: The initial identification of **ID3** mutations in approximately one-third of BL cases |
|
| 16 | +- **ID3 Mutations**: The initial identification of *ID3* mutations in approximately one-third of BL cases |
|
| 17 | 17 | has been consistently corroborated. These mutations, particularly affecting the helix-loop-helix domain, |
| 18 | 18 | are recognized as a hallmark of BL and are rare in other lymphomas. |
| 19 | -- **ARID1A and SMARCA4 Mutations**: Mutations in **ARID1A** and **SMARCA4**, components of the SWI/SNF |
|
| 19 | +- **ARID1A and SMARCA4 Mutations**: Mutations in *ARID1A* and *SMARCA4*, components of the SWI/SNF |
|
| 20 | 20 | chromatin-remodeling complex, have been confirmed in BL. These mutations are often mutually exclusive, |
| 21 | 21 | suggesting that alteration in one is sufficient to disrupt the complex's function. |
| 22 | 22 | - **TP53 Mutations**: Alterations in **TP53** have been consistently observed in BL, underscoring its role |
| 23 | 23 | in the disease's pathogenesis. |
| 24 | 24 | |
| 25 | 25 | ## Expanded Insights |
| 26 | -- **GNA13 Mutations**: The initial study noted mutations in **GNA13**. Further research has highlighted its |
|
| 26 | +- **GNA13 Mutations**: The initial study noted mutations in *GNA13*. Further research has highlighted its |
|
| 27 | 27 | role in BL, particularly in germinal center B cell–derived lymphomas. |
| 28 | 28 | - **Additional Mutations**: Subsequent studies have identified mutations in genes such as **TCF3**, |
| 29 | -**CCND3**, and **DDX3X**, which were not prominently featured in the 2012 study. These findings have |
|
| 29 | +*CCND3*, and *DDX3X*, which were not prominently featured in the 2012 study. These findings have |
|
| 30 | 30 | enriched the understanding of BL's genetic complexity. |
| 31 | 31 | |
| 32 | 32 | ## Less Reproduced Findings |
| 33 | -- **CCT6B, SALL3, FTCD, and PC Mutations**: The study reported mutations in **CCT6B**, **SALL3**, **FTCD**, |
|
| 34 | -and **PC**. However, these findings have not been consistently replicated in subsequent research, suggesting |
|
| 35 | -they may be less central to BL's pathogenesis or represent less common alterations. |
|
| 33 | +- **CCT6B, SALL3, FTCD, and PC Mutations**: The study reported mutations in a large number of genes including *CCT6B*, *SALL3*, *FTCD*, |
|
| 34 | +and *PC*. However, these findings have not been consistently replicated in subsequent research, suggesting |
|
| 35 | +they may be less central to BL's pathogenesis or represent less common alterations. Most of the genes from this study are now in Tier 3. |
|
| 36 | 36 | |
| 37 | 37 | ## Summary of novel genes |
| 38 | 38 |